Inhibitory Effects of α-Arbutin on Melanin Synthesis in Cultured Human Melanoma Cells and a Three-Dimensional Human Skin Model

  • Sugimoto Kazuhisa
    Biochemical Research Laboratory, Ezaki Glico Co., Ltd.
  • Nishimura Takahisa
    Biochemical Research Laboratory, Ezaki Glico Co., Ltd.
  • Nomura Koji
    Biochemical Research Laboratory, Ezaki Glico Co., Ltd.
  • Sugimoto Kenji
    Laboratory of Applied Molecular Biology, Division of Applied Biochemistry, Graduate School of Agriculture and Biological Sciences, Osaka Prefecture University
  • Kuriki Takashi
    Biochemical Research Laboratory, Ezaki Glico Co., Ltd.

書誌事項

タイトル別名
  • Inhibitory Effects of .ALPHA.-Arbutin on Melanin Synthesis in Cultured Human Melanoma Cells and a Three-Dimensional Human Skin Model
  • Inhibitory Effects of アルファ Arbutin on Melanin Synthesis in Cultured Human Melanoma Cells and a Three Dimensional Human Skin Model
  • Inhibitory effects of α-arbutin on melanin synthesis in cultured human melanoma cells and a three-dimentional human skin model

この論文をさがす

抄録

We studied the inhibitory effects of 4-hydroxyphenyl α-glucopyranoside (α-arbutin) on melanogenesis in cultured human melanoma cells, HMV-II, and in a three-dimensional cultured human skin model. α-Arbutin showed no inhibitory effect on HMV-II cell growth at a concentration below 1.0 mM. Melanin synthesis in cells treated with α-arbutin at 0.5 mM decreased to 76% of that in non-treated cells. The cellular tyrosinase activity of HMV-II cells also significantly decreased, while the expression of its mRNA was not affected. Melanin synthesis in a human skin model was also evaluated by the macro- and microscopic observation of its pigmentation as well as by quantitative measurements of melanin. Treatment of the human skin model with 250 μg of α-arbutin did not inhibit cell viability, while melanin synthesis was reduced to 40% of that in the control. These results indicate that α-arbutin is an effective and safe ingredient for skin-lightening.

収録刊行物

被引用文献 (13)*注記

もっと見る

参考文献 (23)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ